1. Home
  2. IMUX vs RVPH Comparison

IMUX vs RVPH Comparison

Compare IMUX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • RVPH
  • Stock Information
  • Founded
  • IMUX 2016
  • RVPH 2006
  • Country
  • IMUX United States
  • RVPH United States
  • Employees
  • IMUX N/A
  • RVPH N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • RVPH Health Care
  • Exchange
  • IMUX Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • IMUX 86.3M
  • RVPH 88.0M
  • IPO Year
  • IMUX N/A
  • RVPH N/A
  • Fundamental
  • Price
  • IMUX $0.98
  • RVPH $2.09
  • Analyst Decision
  • IMUX Strong Buy
  • RVPH Strong Buy
  • Analyst Count
  • IMUX 6
  • RVPH 5
  • Target Price
  • IMUX $12.67
  • RVPH $11.40
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • RVPH 1.8M
  • Earning Date
  • IMUX 02-20-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • IMUX N/A
  • RVPH N/A
  • EPS Growth
  • IMUX N/A
  • RVPH N/A
  • EPS
  • IMUX N/A
  • RVPH N/A
  • Revenue
  • IMUX N/A
  • RVPH N/A
  • Revenue This Year
  • IMUX N/A
  • RVPH N/A
  • Revenue Next Year
  • IMUX N/A
  • RVPH N/A
  • P/E Ratio
  • IMUX N/A
  • RVPH N/A
  • Revenue Growth
  • IMUX N/A
  • RVPH N/A
  • 52 Week Low
  • IMUX $0.92
  • RVPH $0.60
  • 52 Week High
  • IMUX $2.11
  • RVPH $4.83
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • RVPH 60.41
  • Support Level
  • IMUX $0.94
  • RVPH $1.78
  • Resistance Level
  • IMUX $1.02
  • RVPH $2.15
  • Average True Range (ATR)
  • IMUX 0.06
  • RVPH 0.15
  • MACD
  • IMUX 0.00
  • RVPH 0.02
  • Stochastic Oscillator
  • IMUX 44.96
  • RVPH 88.30

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: